Active ingredients: lenvatinib
What it is used for
Endometrial carcinoma LENVIMA, in combination with pembrolizumab, is indicated for the treatment of patients with advanced endometrial carcinoma that is not microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR), who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation., Differentiated thyrthyroid cancer (DTC) LENVIMA is indicated for the treatment of patients with progressive, locally advanced or metastatic, radioactive iodine (RAI) refractory differentiated thyroid cancer (DTC).,Renal cell carcinoma (RCC) LENVIMA, in combination with pembrolizumab, is indicated for the first-line treatment of adult patients with advanced renal cell carcinoma (RCC).,LENVIMA, in combination with everolimus, is indicated for the treatment of adult patients with advanced renal cell carcinoma (RCC) whose disease has progressed following one prior vascular endothelial growth factor targeted therapy.,Hepatocellular carcinoma (HCC) LENVIMA is indicated for the first-line treatment of patients with unresectable hepatocellular carcinoma (HCC).
How to take it
The way to take this medicine is: Oral. This medicine is taken by mouth.
- Store below 30 degrees Celsius
- Shelf lifetime is 48 Months.
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
The 10mg capsule is a yellow body and a yellowish-red cap, marked in black ink with [lunate epsilon symbol] on the cap and LENV 10mg on the body
Do I need a prescription?
This medicine is available from a pharmacist and requires a prescription. It is
Is this medicine subsidised?
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on August 1, 2022. To learn more about this subsidy, visit the Pharmaceutical Benefits Scheme (PBS) website.
Pregnant or planning a pregnancy?
For the active ingredient lenvatinib
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
For side effects, taking other medicines and more
Download consumer medicine information leaflet (pdf) from the Therapeutic Goods Administration (TGA) website
Reporting side effects
This medicine is under additional monitoring as it is new or being used in a different way. You can help identify new safety information by reporting any side effects you may get.